Replies to post #31358 on NorthWest Biotherapeutics Inc (NWBO)

[f3tt3f]

Excuse me?

"The recent rGBM arm data doesn't look as promising as I had hoped. 15.1 months is not good enough. "

The median overall survival for this indication is between 8 and 10 months.
A greater than 50% improvement is better than good enough.